Genmab A/S (GMAB) reported another year of rising global sales for its flagship antibody therapy DARZALEX (daratumumab), with 2025 net trade sales reaching $14.35 billion according to figures reported by Johnson & Johnson.
The performance reflects continued expansion of the therapy across multiple myeloma treatment settings and sustained uptake of the subcutaneous formulation, DARZALEX FASPRO, in the United States.
DARZALEX, a CD38- targeting monoclonal antibody, is one of the most widely used therapies in multiple myeloma and remains a key revenue driver for Genmab through its global royalty agreement with Johnson & Johnson (Janssen Biotech).
Year-Over-Year Sales Growth
Net sales of DARZALEX rose to $14.35 billion in 2025, an increase from $11.67 billion in 2024, reflecting continued global demand for the therapy.
Growth was driven by higher U.S. sales, which reached $8.27 billion compared with $6.59 billion in the prior year, alongside strong performance in international markets, where sales increased to $6.08 billion from $5.08 billion in 2024. The year-over-year expansion highlights broader adoption across treatment settings and sustained uptake of the subcutaneous formulation.
The company is scheduled to report its annual results for 2025 on February 17, 2026.
GMAB has traded between $17.24 and $35.43 over the past year. The stock is currently trading in the pre-market at $32.00, up 2.14%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.